Get the Stockscreener App
12.36
2.74%
0.33
Pre-market:
12.49
0.13
+1.05%
Dyne Therapeutics Inc stock is traded at $12.36, with a volume of 1.76M.
It is up +2.74% in the last 24 hours and down -11.21% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$12.03
Open:
$12.38
24h Volume:
1.76M
Relative Volume:
1.02
Market Cap:
$1.40B
Revenue:
-
Net Income/Loss:
$-294.51M
P/E Ratio:
-3.4719
EPS:
-3.56
Net Cash Flow:
$-244.42M
1W Performance:
+1.48%
1M Performance:
-11.21%
6M Performance:
-62.62%
1Y Performance:
-54.39%
1-Day Range:
$11.91
$12.47
1-Week Range:
$11.18
$12.75
52-Week Range:
$11.18
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
12.36 | 1.40B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Benzinga
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating - Yahoo Finance UK
BMO Capital Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation - Nasdaq
BMO Capital Initiates Dyne Therapeutics Inc at Outperform With $50 Price Target -March 12, 2025 at 07:22 am EDT - Marketscreener.com
Dyne Therapeutics: Innovative Approaches and Promising Clinical Programs Drive Buy Rating - TipRanks
Dyne Therapeutics initiated with an Outperform at BMO Capital - TipRanks
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum - GlobeNewswire
Neuromuscular Disease Breakthroughs: Dyne Therapeutics Reveals Latest Progress at CNS Forum - StockTitan
Dyne Therapeutics (NASDAQ:DYN) Research Coverage Started at Scotiabank - Defense World
Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World
Trend Tracker for (DYN) - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Scotiabank - MarketBeat
Scotiabank Initiates Coverage of Dyne Therapeutics (DYN) with Sector Outperform Recommendation - Nasdaq
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Thinking Of Investing In Dyne Therapeutics Inc (NASDAQ: DYN) Stock? Read This First - Stocks Register
Scotiabank sets Dyne Therapeutics stock target at $50, cites entry point - Investing.com India
Dyne Therapeutics initiated with an Outperform at Scotiabank - TipRanks
Y Intercept Hong Kong Ltd Has $230,000 Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.4% on Analyst Downgrade - Defense World
Dyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Chardan Capital - Defense World
What is HC Wainwright’s Estimate for DYN Q1 Earnings? - Defense World
Piper Sandler Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $48.00 - Defense World
HC Wainwright Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $46.00 - Defense World
Rhumbline Advisers Boosts Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
HC Wainwright Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $46.00 - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells 2,598 Shares of Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Hits New 12-Month LowWhat's Next? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Dyne Therapeutics stock target cut to $46 at H.C. Wainwright By Investing.com - Investing.com Canada
Dyne Therapeutics price target lowered to $48 from $53 at Piper Sandler - TipRanks
RBC Cuts Price Target on Dyne Therapeutics to $41 From $45, Keeps Outperform, Speculative Risk - Marketscreener.com
Buy Rating for Dyne Therapeutics: Promising Accelerated Approval Potential for DYNE-101 and DYNE-251 - TipRanks
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Dyne Therapeutics Advances Clinical Programs Amid Financial Losses - TipRanks
Dyne Therapeutics (DYN) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Dyne Therapeutics Q4 Net Loss Narrows; Shares Rise -February 27, 2025 at 09:42 am EST - Marketscreener.com
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
DYNE THERAPEUTICS Earnings Results: $DYN Reports Quarterly Earnings - Nasdaq
Dyne Therapeutics, Inc. Q4 Loss Beats Estimates - Nasdaq
Can Dyne's $783M War Chest and Fast-Tracked DM1 Program Transform Muscle Disease Treatment? - StockTitan
Dyne Therapeutics, Inc. SEC 10-K Report - TradingView
How To Trade (DYN) - Stock Traders Daily
Dyne therapeutics chief scientific officer sells $36,242 in stock By Investing.com - Investing.com South Africa
Dyne therapeutics chief scientific officer sells $36,242 in stock - Investing.com India
Dyne Therapeutics CSO Sells Shares to Satisfy Tax Obligations - TradingView
First Week of April 17th Options Trading For Dyne Therapeutics (DYN) - Nasdaq
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Myotonic Dystrophy Pipeline Analysis 2024: FDA Approvals - openPR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc.(DYN) And Encourages Investors to Connect - ACCESS Newswire
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):